Sep 23, 2016 | IMV Inc., News
Presentations at RSV16, World Vaccine Congress Europe and IDWeek Conferences Highlight Company’s Progress in Using DepoVax™-based Agents to Address Respiratory Syncytial Virus (RSV) and Life-Threatening Malaria
Halifax, Nova Scotia, September 23, 2016 – Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX: IMMVF), a clinical-stage vaccine and immunotherapy company, today announced planned data presentations at upcoming scientific meetings in conjunction with collaborators at
VIB, the Flemish life sciences research institute, and the
Canadian Center for Vaccinology (CCfV). These presentations will focus on DPX-RSV, Immunovaccine’s lead infectious disease candidate in development for the prevention of respiratory syncytial virus (RSV).
Details for the presentations are as follows:
Presentation at 10th International Respiratory Syncytial Virus Symposium (RSV16), September 28-October 1, 2016 in Patagonia, Argentina
Session: Poster Session 1; Poster 393
Session Date: September 28-29, 2016
Session Location: Llao Llao Hotel, Tronador Room in Bariloche, Argentina
Session Time: Afternoon of September 28 – Afternoon of September 29
Presentation Title: “Live Cell Imaging of Antibody Dependent Phagocytosis and Trogocytosis of RSV And Influenza Virus Infected Cells”
Presentations at World Vaccine Congress Europe, October 10-12, 2016 in Barcelona, Spain
Session: Respiratory
Session Date: Monday, October 10, 2016
Session Location: Fairmount Rey Juan Caros, Barcelona, Spain
Session Time: 4:45 PM CEST
Presentation Title: “Preclinical and Clinical development of a new HRSV vaccine based on the Small Hydrophobic protein that instructs macrophages to clear infected cells”
Session: Poster Sessions 1 and 2
Session Date: Monday, October 10 – Tuesday, October 11, 2016
Session Location: Fairmount Rey Juan Caros, Barcelona, Spain
Session Time: 1:15 – 4:45 PM CEST
Presentation Title: “Single dose immunization with DepoVax™ induces potent, long-lasting antibodies to PfEMP1: a novel malaria vaccine approach”
Presentation at IDWeek, October 26-30, 2016 in New Orleans, Louisiana
Session: Clinical Infectious Diseases: Respiratory Infections
Session Date: Friday, October 28, 2016
Session Time: 12:30 PM – 2:00 PM CT
Session Location: New Orleans Convention Center Poster Hall
Presentation Title: “A Phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SH antigen and a novel adjuvant DepoVax™, or SH antigen co-administered with aluminum hydroxide, or placebo to healthy adults ≥50-64 years of age”
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at
www.imvaccine.comForward-looking Statement
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals and the matters discussed under “Risk Factors and Uncertainties” in Immunovaccine’s Annual Information Form filed on March 29, 2016. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
]]>
Sep 22, 2016 | News, TruLeaf
here
TruLeaf is pleased to announce that its President & CEO, Gregg Curwin, has been given the Clean50 award by Delta Management Group, for developing and scaling TruLeaf’s Smart Plant System®. Each year Delta Management Group recognises 50 individuals from across Canada who have developed new technologies or instituted company-wide changes that create a positive net environmental impact from business operations. Delta’s criteria in determining Honourees is to carefully consider actual measurable accomplishments, demonstrated innovation, collaboration with other organizations, and the power of the Honouree’s contribution to inspire other Canadians to take similar action.
The Clean50 award provides validation for Gregg’s hard work in turning the idea of multi-level indoor growing into a viable and profitable business.
“I was truly honoured to be nominated to receive this prestigious award from Delta Management Group,” said Gregg Curwin. “Our company has come a long way in taking an idea and building a strong business that is sustainable in every sense of the word. The award will be shared with all of my hard-working colleagues at TruLeaf.”
The average pound of California lettuce requires a whopping 160 litres of water. By combining that same water with collected rainwater and rigorous filtration, Gregg’s indoor farm can grow 80 pounds of leafy greens, demonstrating that indoor multi-level farming has moved from concept to reality. TruLeaf was founded to design and build a prototype indoor commercial farming system to grow leafy greens and herbs for retail and wholesale markets with the idea of getting nutritious, local food to Atlantic Canadians without pesticides or run off. With the first one up and growing nearly 200,000 lbs. of fresh produce annually, the next stop is Toronto.
“Gregg Curwin was chosen after rigorous screening and research by Delta Management, with advice from internal researchers and external advisors, and was among Honourees selected from an initial pool of over 500 well qualified nominees,” said Gavin Pitchford, CEO, Delta Management Group.
Gregg Curwin has successfully owned and operated several businesses in the medical device and biologics industry in the Atlantic Canadian region. Upon further investigation into the current health care system, he quickly realised the gateway to a healthy population was nutritious local food. The best way to make this accessible in Atlantic Canada was to build an indoor farm.
“Our farm is extremely efficient in its use of resources, but more importantly, it creates access to really clean healthy food for Atlantic Canadians. It is stimulating the local economy, challenging the status quo, and is working to improve food security in our region.”
About TruLeaf
TruLeaf is a revolutionary company that improves predictability in agriculture. Using its Smart Plant Systems® technology, it creates efficient, controlled, indoor farms that can be located anywhere, from the heart of an urban centre to areas with harsh climates or remote locations. Its team includes world-leading expertise in plant science, environmental control, new product development, marketing and supply chain management. GoodLeaf Farms is the exclusive Canadian licensee of the Smart Plant System®.
Media Contact:
Greg Veinott
[email protected]
902-452-6558
www.truleaf.ca
About Delta Management Group
Leading sustainability and clean tech search firm Delta Management Group in 2011 founded, and remains the steward of the Canada’s Clean50 awards, created to annually identify, recognize and connect 50 sustainability leaders from every sector of Canadian endeavor, in order to facilitate understanding, collaboration and innovation in the fight to keep climate change impacts below 1.5 degrees. Ancillary awards also recognize 10 Emerging Leaders and the Top 15 Sustainability Projects of the year.
Media Contact:
Gavin Pitchford
[email protected]
416-925-2005 x 2300
www.deltamanagement.com]]>
Sep 21, 2016 | News, Spring Loaded Technology
here
Research scientists find the LevitationTM Knee Brace enables users to perform 20 percent more squats
HALIFAX, NS – Sept. 20, 2016 – Spring Loaded Technology today reports the findings of a recent third-party study which links its LevitationTM, the world’s first compact bionic knee brace, to a significant reduction in factors that can lead to muscle fatigue. Research scientists observed the oxygen intake, carbon dioxide production and muscle activity of three healthy individuals as they repeated a squat to stand task with and without the assistance of the knee brace.
The study found that the LevitationTM Knee Brace, which uses a liquid spring technology to store energy as the leg is bent and return it as the leg is straightened, requires significantly less exertion from the user during energy expensive movements like rising to a stand from a full squat or crouched position. Data from the study revealed that participants used 25 percent less oxygen during the task cycle when compared to their consumption without the brace’s assistance. The researchers also found a drastic 40 percent reduction in carbon dioxide production.
The study was performed through the NSERC Engage Program at the University of New Brunswick by research scientists, Dr. Chris McGibbon in the Faculty of Kinesiology and Abeer Mohamed Abdelhady, PhD Candidate in the Dept. Mechanical Engineering.
“With the knee brace’s assistance, participants consumed less energy and were able to do more physical activity as measured with our squat test,” said Dr. Chris McGibbon. “The participants in this study also demonstrated a reduced respiratory exchange ratio (RER) while wearing the LevitationTM, meaning that they were burning more fat stores than carbohydrates. These findings are consistent with Spring Loaded Technology’s claim that LevitationTM reduces factors known to be associated with muscle fatigue—an exciting and unique accomplishment for knee braces and the field of bionics.”
The findings also support the brace’s ability to reduce demand on the muscles in order to improve performance, with participants showing an 85 percent reduction of activity in the quadriceps muscles and a 50 percent reduction of activity in the hamstring muscles during the squat task. Study participants were also able to perform up to 20 percent more squats when wearing the brace compared to the number of squats achieved when their knees were unassisted.
This data was drawn at the Levitation™ Knee Brace’s maximum assistance level. The level of assistance is adjustable and can be tailored to the user’s needs. This allows the user to specify different settings for different activities, or if the individual is recovering from an injury, to gradually reduce the level of assistance provided to zero as they recover their full strength.
“LevitationTM was designed to go above and beyond joint stabilization to assist strength and reduce fatigue. The result is a product intended to enhance mobility and expedite rehabilitation,” said Chris Cowper-Smith, CEO at Spring Loaded Technology. “It was important to us to have a study that shows our customers what sets us apart in the marketplace as they make an informed decision about which brace is best for them.”
LevitationTM Knee Braces ($1,750 USD) are currently available for pre-order.
To learn more about Spring Loaded Technology, visit www.springloadedtechnology.com.
About Spring Loaded Technology
Spring Loaded Technology is an award-winning company that is introducing compact and high-performance bionic knee braces to the world. Based in Nova Scotia, Canada, the company has revolutionized knee bracing technology to enhance the strength and power of the leg muscles. By increasing leg strength, this technology can be used in a wide range of applications including: mobility assistance, fatigue reduction, injury prevention and rehabilitation, and performance enhancement. The company was founded in 2012.
Media Contact
Melissa Landy
Uproar PR for Spring Loaded Technology
321-236-0102 x233
[email protected]]]>
